Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Tocilizumab AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
322 results
  • Rethinking interleukin-6 blockade for treatment of COVID-19. [Journal Article]
    Med Hypotheses. 2020 Jun 27; 144:110053.Scherger S, Henao-Martínez A, … Shapiro L
  • Interleukin-6 (IL-6) is a pleiotropic cytokine with effects in immune regulation, inflammation, and infection. The use of drugs that inhibit IL-6 biological activity has been proposed as a treatment for patients with Coronavirus Disease 2019 (COVID-19). The rationale for this approach includes commitment to the concept that inflammation is a cause of lung damage in COVID-19 and belief that IL-6 i…
  • Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. [Review]
    Front Immunol. 2020; 11:1708.Tang Y, Liu J, … Wen C
  • Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has caused 347,192 deaths around the world. The current evidence showed that severely ill patients tend to have a high concentration of pro-inflammatory cytokines, such as interleukin (IL)-6, compared to those who are moderately …
  • Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients. [Letter]
    J Intern Med. 2020 Aug 03 [Online ahead of print]Patel K, Gooley TA, … Pagel JM
  • Severely ill COVID-19 patients have a high risk of admission to the intensive-care unit (ICU) and requirement for mechanical ventilation (MV), with in-hospital mortality reported as 18-79% globally.1-4 . Among ICU patients in the United States (US), centers have reported 50% mortality.5,6 Tocilizumab, an IL-6 receptor (IL-6R) antagonist, is FDA approved for the management of CAR T-cell related Cy…
  • COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. [Preprint]
    medRxiv. 2020 Jul 26Strohbehn GW, Heiss BL, … Reid PD
  • Background Interleukin-6 (IL-6)-mediated hyperinflammation may contribute to the high mortality of coronavirus disease 2019 (Covid-19). Tocilizumab, an IL-6 receptor blocking monoclonal antibody, has been repurposed for Covid-19, but prospective trials and dose-finding studies in Covid-19 are lacking. Methods We conducted a phase 2 trial of low-dose tocilizumab in hospitalized adult patients with…
  • [COVID-19 from the Perspective of Haematology and Haemostaseology]. [Journal Article]
    Dtsch Med Wochenschr. 2020 Jul; 145(15):1044-1050.Spiekermann K, Subklewe M, … von Bergwelt-Baildon M
  • Infection with SARS-COV-2 leads to a number of pathologies in the hematopoetic system that have significant impact on clinical symptoms and mortality. There are 3 stages of infection: (1) early upper respiratory tract infection with fever and lymphopenia (2) pulmonary phase and (3) hyperinflammatory phase with the clinical signs of organ failure such as ARDS/shock. Hyperinflammation, which is tri…
  • [COVID-19 pneumonia]. [Review]
    Internist (Berl). 2020 Aug; 61(8):793-803.Pfeifer M, Hamer OW
  • Coronavirus disease 2019 (COVID-19) continues to pose a major global threat. Although a wide range of organ manifestations have now been described, the respiratory system remains in the forefront in terms of the course of infection. Severe pneumonia can develop and is generally prognostically relevant. The following article discusses currently known features of these pulmonary manifestations from…
  • Appropriate use of Tocilizumab in COVID-19 Infection. [Journal Article]
    Int J Infect Dis. 2020 Jul 26 [Online ahead of print]Keske Ş, Tekin S, … Ergönül Ö
  • CONCLUSIONS: Earlier use of TCZ in COVID-19 infection is beneficial for survival, length of hospitalization, and duration of oxygen support. Our recommendation for the administration of TCZ is based on the increase in requirement of the oxygen support, progression in the thorax computerized tomography, and elevation of inflammation markers, including IL-6, CRP, ferritin, and D-dimer and decrease in percent of lymphocyte.
  • Colorectal surgery obesity-related morbidity during COVID-19. [Journal Article]
    Surg Obes Relat Dis. 2020 Jul 09 [Online ahead of print]Montorfano L, Miret R, … Wexner SD
  • Tocilizumab, a monoclonal antiinterluekin-6 receptor antibody, has been empirically used in the treatment of cytokine release syndrome associated with severe coronavirus disease 2019 infections. The efficacy and safety of these medications for these patients is unknown. The purpose of this report was to present a case of acute large bowel perforation in a morbidly obese patient with coronavirus d…
  • Extremely Preterm Infant Born to a Mother With Severe COVID-19 Pneumonia. [Case Reports]
    J Investig Med High Impact Case Rep. 2020 Jan-Dec; 8:2324709620946621.Easterlin MC, De Beritto T, … Ramanathan R
  • Little is known about the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pregnant women, fetuses, and neonates, especially when the virus is contracted early in pregnancy. The literature is especially lacking on the effects of SARS-CoV-2 on extremely preterm (<28 weeks gestation) infants who have underdeveloped immune systems. We report the case of an extremely preterm…
New Search Next